< Back to latest news & events

News

Oral Proceedings by videoconference (VICO) in oppositions proceedings to become permanent

November 2022

The pilot project for oral proceedings in opposition proceedings by video conference (VICO) started during the pandemic and has received positive feedback.[1]

The President of the EPO has therefore declared (Decision of 22 November 2022) that, as of 1 January 2023, VICOs will become the default format for oral proceedings in opposition. Only in exceptional circumstances when the opposition division permits it, will oral proceedings in opposition be conducted in person.

The president believes that VICO has enabled parties to save on time and money whilst reducing carbon emissions from travelling in person.

Accordingly oral proceedings will only be held in person if requested by a party or at the instigation of the Opposition Division if there are serious reasons against holding the proceedings by video conference. If a party’s request is refused the refusal is not separately appealable.

Given the experience during the pandemic, and as set out in the Pilot Project Final Report [1], the taking of evidence, including hearing witnesses and inspection, has been successfully conducted by VICO and so is not likely to amount to serious reasons for conducting oral proceedings in person. An exception may be where inspection cannot be adequately conducted using video equipment.

Please see here for the official notice from the EPO.

The decision of the President does not affect Oral Proceedings at the Boards of Appeal. Indeed, in the Enlarged Board of Appeal Decision G1/21 the Enlarged Board clearly stated that whilst oral proceedings by VICO were compatible with the right to be heard enshrined in the EPC they were suboptimal compared with in-person hearings and, as such, in-person hearings should, in the absence of a pandemic, be the default option (Reason 45).

Accordingly we do not expect the President’s Decision to have a knock-on effect at the Board of Appeal.

For further information please contact Dr Chris Moore, Head of Oppositions & Appeals.

[1] Pilot Project Final Report November 2022 (here) – over 77% of respondents found oral proceedings to be “good” or “very good”

Latest updates

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article